Abstract

Background and Objectives: Kathrat-i-Ḥayḍ, or Heavy Menstrual Bleeding (HMB), is one of the most common reasons women are referred to gynaecologists, with a prevalence of 10-15%. Despite its frequency, scientific validation has been lacking. Therefore, an attempt was made to evaluate the efficacy of Qurs Kahruba in treating HMB. Methodology: Diagnosed patients (n=30), both married and unmarried, aged between 18-40 years, with regular cycles experiencing heavy bleeding in duration, amount of flow, or both, were included in the study conducted at NIUM Hospital. Qurs Kahruba was administered orally as two tablets thrice daily for 5 days during menstruation for 3 consecutive cycles. The primary outcome was measured using the PBLAC (Pictorial Blood Loss Assessment Chart) scale to assess the effect of Qurs Kahruba on menstrual blood loss at each cycle. The secondary outcome involved using the Multi-Attribute Utility Assessment (MAUA) scale to determine the improvement in quality of life (QoL) at each follow-up. Results were analyzed using the Student's t-test and paired proportion tests. Result: The PBLAC scores at baseline and after the 3rd cycle were 555.63±172.72 and 103.87±39.72, respectively, showing a significant difference (P <0.001). The MAUA scores at baseline and after the 3rd cycle were 35.90±17.34 and 97.39±2.86, respectively, also demonstrating a significant difference (P <0.001) and indicating an improvement in quality of life (QoL). Conclusion: Qurs Kahruba was found effective in reducing HMB in terms of both duration and amount of flow, as well as in improving the quality of life (QoL) of the patients. Furthermore, it was found to be safe and well-tolerated by the patients.